EM1607C "Immunotherapy in Kidney Cancer: The Past, Present and Future" (IM GR-071516)
Purpose and Overview: The purpose of the presentation is to highlight the development of immunotherapy for renal cell carcinoma. The audience will be introduced to some basic preclinical and clinical concepts of tumor immunotherapy. Long considered one of the more “immunogenic” tumors we will review the early experience with first generation immunotherapies, i.e. cytokine like interferon alpha and interleukin 2 and then discuss the current state of kidney cancer immunotherapy with immune checkpoint inhibitors like nivolumab. Lastly, we will point out strategies to maximize the benefit of immunotherapy in kidney cancer with rationally designed treatment approaches.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Describe the required components necessary for a successful anti-tumor immune response
- Explain the expected efficacy and side effect profile of the recently approved anti-PD1 immune checkpoint inhibitor nivolumab
- Outline therapeutic strategies to further increase the potential of immunotherapies in kidney cancer
Hans Hammers, M.D., Ph.D.
Division of Hematology / Oncology
- 1.00 AMA